Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 7Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neuroectodermal Tumors, Primitive 2Hypoxia 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

TH 302 2pasireotide 1omburtamab I-131 1gallium Ga 68 dotatate 1entinostat 1Thalidomide 1Sunitinib 1Radiotherapy, Image-Guided 1Nivolumab 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × TH 302 × Gastrointestinal × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01381822 2014-04-21

TH-CR-410

Threshold Pharmaceuticals

Phase 1 Unknown
58 enrolled
GastrointestinalSarcoma

Neuroectodermal Tumors, Primitive, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡